DOP55 A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE
Gerassimos J. Mantzaris(European CanCer Organisation), Andrés Yarur(Cedars-Sinai Medical Center), M Bassel, Christian Agboton, Sumit Saha(Takeda (Canada)), Brian Bressler(University of British Columbia), Christina Kifnidi, Dirk Demuth(Takeda (Singapore)), Neil R. Brett(McGill University), Michelle Luo(University of North Carolina at Chapel Hill), Shashi Adsul(Takeda (United States)), Chris Colby(Kaiser Permanente), Uri Kopylov(Sheba Medical Center), Shu Wang(Xi'an Jiaotong University), Claudia Lopez(Takeda (United States))
Cited by 4
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
|Journal of Crohn s and Colitis|2019|1.1k
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
|Journal of Crohn s and Colitis|2021|1.1k